Clinical Trial Update: A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib [Phase 2]

View source ↗

Summary

Phase 2 trial in rheumatoid arthritis patients completed; study terminated with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ABBV-105
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA) | Phase 2 | Status: TERMINATED | Results posted: 2021-09-16